MDMA in two dose strengths shows effectiveness in reducing PTSD symptoms
The Brown University Psychopharmacology Update September 1, 2018 Peer reviewed DOI: 10.1002/pu.30352
Summary
Military veterans and public safety officers with chronic PTSD showed a reduction in symptoms when treated with the psychedelic drug MDMA alongside psychotherapy. In a randomized trial, doses of 75 mg and 125 mg administered in two sessions, spaced 3 to 5 weeks apart, were found to be more effective than a control dose of 30 mg.
Study at a glance
| Design | randomized controlled trial |
|---|---|
| Population | military veterans and public safety officers with chronic PTSD |
| Key finding | MDMA doses of 75 mg and 125 mg were more effective than a control dose of 30 mg in reducing PTSD symptoms. |
Abstract
Military veterans and public safety officers with chronic post‐traumatic stress disorder (PTSD) experienced a reduction in symptoms when the psychedelic drug 3,4‐methylenedioxymethamphetamine (MDMA) was given in conjunction with psychotherapy, a randomized trial has found. Doses of 75 mg and 125 mg, each given in two experimental sessions spaced 3 to 5 weeks apart, were more effective than a control dose of 30 mg, researchers reported.